Once a Week Is Enough: Lilly's Onswik Approval Reshapes the Insulin Market

For the roughly 38 million Americans living with diabetes, the daily ritual of insulin injections is one of the most persistent burdens of managing the disease. On September 24, 2026, the U.S. Food and Drug Administration approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. The approval marks a meaningful shift in how the condition can be managed and sets the stage for a direct commercial battle between two of the world's largest pharmaceutical companies.

Onswik's FDA clearance is the drug's fourth global regulatory approval, following earlier green lights in Europe, Mexico, and Japan. Lilly has said the drug will be made available in the U.S. "in the coming months," though pricing and access details have not yet been disclosed. The approval was supported by data from the Phase 3 QWINT clinical trial program, which enrolled approximately 3,400 adults and demonstrated that Onswik was non-inferior to standard once-daily basal insulins, including insulin glargine and Novo Nordisk's insulin degludec (Tresiba). In the QWINT-2 trial, Onswik reduced HbA1c by 1.34%, compared with a 1.26% reduction in patients taking degludec.

The Patient Burden Argument

The clinical case for once-weekly insulin is straightforward: fewer injections mean less friction. A patient on a daily basal insulin regimen administers more than 365 injections per year. Onswik, taken once weekly, reduces that number by more than 300. For patients who struggle with adherence, needle anxiety, or the cognitive load of daily disease management, that reduction is not trivial. Improved adherence to basal insulin therapy is associated with better glycemic control and fewer long-term complications, including cardiovascular disease, kidney failure, and neuropathy.

Yet the approval also comes with an important caveat. Onswik's label explicitly states the drug should not be used in patients with type 1 diabetes due to an increased risk of hypoglycemia. This mirrors the regulatory path of Novo Nordisk's Awiqli (insulin icodec), which received FDA approval in March 2026 after a prolonged regulatory journey that included two prior rejections. Awiqli became the first once-weekly insulin available in the U.S., but Lilly's entry now gives prescribers and patients a choice in a category that barely existed a year ago.

A New Front in the Lilly-Novo Rivalry

The approval deepens what has become one of the most consequential rivalries in modern pharma. Lilly and Novo Nordisk have been locked in competition across the GLP-1 and obesity drug markets, with Lilly's tirzepatide (Mounjaro, Zepbound) and Novo's semaglutide (Ozempic, Wegovy) dominating headlines and investor attention for the past several years. The once-weekly insulin space opens a new competitive dimension, one that is arguably more foundational to diabetes care than the newer weight-loss drugs.

Basal insulin remains the backbone of type 2 diabetes management for millions of patients who have progressed beyond oral medications. The market is large, relatively stable, and dominated by a handful of established products. Introducing a weekly formulation does not simply add a new drug to the mix; it potentially resets patient and physician expectations about what insulin therapy should look like. If once-weekly becomes the new standard of care, the companies that establish early market share and formulary positioning will have a durable advantage.

What Comes Next

The commercial dynamics will hinge on several factors that remain unresolved. Pricing will be critical. Insulin pricing in the U.S. has been a politically charged issue, and both Lilly and Novo have faced pressure to cap out-of-pocket costs. Whether Onswik is priced at a premium to daily insulins, or positioned as a cost-competitive alternative, will shape its uptake among payers and patients alike.

Physician adoption will also take time. Prescribers are generally cautious about switching stable patients to new formulations, particularly when the primary benefit is convenience rather than superior efficacy. The non-inferiority data from QWINT is reassuring, but real-world evidence on long-term outcomes, hypoglycemia rates, and patient-reported quality of life will be needed to build broader confidence.

Still, the direction of travel is clear. The insulin market is moving toward less frequent dosing, and both Lilly and Novo are now positioned to lead that transition. For patients who have spent years measuring their lives in daily injections, the arrival of a once-weekly option represents something more than a regulatory milestone. It is a tangible improvement in the texture of daily life with a chronic disease, and that is a story worth paying attention to.